Edesa Biotech (Nasdaq: EDSA) reports Q1 2026 results, financials for three months ended December 31, 2025.
Today, Edesa Biotech, Inc. (Nasdaq:EDSA), a company specializing in host-directed therapeutics for immuno-inflammatory diseases, released financial data for the quarter ending December 31, 2025. The report also included a business update, highlighting their progress in the clinical-stage biopharmaceutical field.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments